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Abstract The ‘ribosomal stress (RS)-p53 pathway’ is triggered by any stressor or genetic 
alteration that disrupts ribosomal biogenesis, and mediated by several ribosomal proteins (RPs), 
such as RPL11 and RPL5, which inhibit MDM2 and activate p53. Inosine monophosphate (IMP) 
dehydrogenase 2 (IMPDH2) is a rate-limiting enzyme in de novo guanine nucleotide biosynthesis 
and crucial for maintaining cellular guanine deoxy- and ribonucleotide pools needed for DNA and 
RNA synthesis. It is highly expressed in many malignancies. We previously showed that inhibition of 
IMPDH2 leads to p53 activation by causing RS. Surprisingly, our current study reveals that Inauzhin 
(INZ), a novel non-genotoxic p53 activator by inhibiting SIRT1, can also inhibit cellular IMPDH2 
activity, and reduce the levels of cellular GTP and GTP-binding nucleostemin that is essential for 
rRNA processing. Consequently, INZ induces RS and the RPL11/RPL5-MDM2 interaction, activating 
p53. These results support the new notion that INZ suppresses cancer cell growth by dually 
targeting SIRT1 and IMPDH2.
DOI: 10.7554/eLife.03077.001
Introduction
With ∼22 million people living with cancers that are highly associated with alterations of multiple 
molecules and pathways, it is important to develop a multiple molecules-targeted therapy that can 
effectively kill cancer cells. The tumor suppressor p53 pathway is one such a target because nearly all 
cancers show defects in this pathway. Approximately 50% of human cancers have mutations in the 
TP53 gene itself, while the rest of them harbor functionally inactive p53 proteins, because active p53 
can trigger cell growth arrest, apoptosis, autophagy, and/or senescence, which are detrimental to 
cancer cells (Vogelstein et al., 2000; Vousden and Prives, 2009), and impede cell migration, metabolism, 
and/or angiogenesis. A major mechanism for functional inactivation of p53 is through overexpression 
of two chief p53 suppressors, MDM2 and MDMX, which work together to inactivate p53 by directly 
interacting with p53, inhibiting its transcriptional activity and mediating its ubiquitin dependent 
degradation (Wade et al., 2010; Huang et al., 2011; Tollini and Zhang, 2012). This MDM2/MDMX-
mediated p53 degradation is also facilitated by SIRT1, a nicotinamide adenine dinucleotide (NAD+)-
dependent deacetylase (Vaziri et al., 2001; Cheng et al., 2003). SIRT1 is highly expressed in human 
cancers due to down regulation of another p53 target tumor suppressor called hypermethylated in 
cancer-1 (HIC-1) (Chen et al., 2005).
Our previous study identified a small molecule named Inauhzin (INZ) that effectively inhibits SIRT1 
activity and induces p53 acetylation, leading to the increase of p53 level and activity (Zhang et al., 
2012b). Consequently, INZ induces p53-dependent apoptosis and senescence in various p53-wild 
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type human cancer cells, such as H460, and HCT116 by inducing the expression of p53-dependent 
transcriptome (Liao et al., 2012). INZ markedly inhibits the growth of H460 or HCT116 xenograft 
tumors, but is not toxic to normal cells and tissues. Also, INZ sensitizes the anti-cancer effect of cisplatin, 
doxorubicin, or Nutlin-3 (an MDM2 inhibitor) as tested in xenograft cancer models (Zhang et al., 
2012c; Zhang et al, 2013). Thus, this small molecule presents as a promising contender for a molecule-
targeted anti-cancer therapy. Since its discovery, we have optimized INZ (Zhang et al., 2012a) and 
determined additional cellular proteins that INZ might target via a set of biochemical, proteomic, and 
cell-based analyses. As detailed below, our study unveils inosine monophosphate (IMP) dehydrogenase 
2 (IMPDH2) as a novel cellular target of INZ.
Results and Discussion
Identification of IMPDH2 as a cellular target of INZ
IMPDH is the key metabolic enzyme supplying guanine nucleotides to a cell as the first and rate-limiting 
enzyme of de novo GTP biosynthesis by catalyzing NAD+-dependent oxidation of IMP to xanthosine 
monophosphate (XMP) (Zimmermann et al., 1995; Zhang et al., 1999). IMPDH2 is the predominant 
isoform among its two isoenzymes, and often highly expressed in proliferating cells and neoplastic 
tissues (Ishitsuka et al., 2005; Gu et al., 2003), correlated to drug resistance, and thus has been used 
as a validated target for immunosuppressive (mycophenolic acid [MPA] [Sintchak et al., 1996] and 
mizoribine [Gan et al., 2003]), antiviral (ribavirin [Prosise et al., 2002]), and cancer-chemotherapeutic 
development [tiazofurin] (Malek et al., 2004; Gu et al., 2005; Chen and Pankiewicz, 2007; Borden 
and Culjkovic-Kraljacic, 2010).
Interestingly, by performing a biotin-INZ avidin affinity purification coupled with mass spectrom-
etry (MS) analysis, we identified IMPDH2 as one of the top candidate proteins that INZ specifically 
eLife digest Cancer develops when cells lose the ability to control their own growth. About half 
of cancerous tumors carry a dysfunctional version of a protein called p53, while the other half have 
defects in proteins that are important for p53's production and function. When a healthy cell is 
exposed to damaging chemicals or agents, the p53 protein triggers responses that are aimed at 
repairing the damage. However, if these attempts fail, p53 causes the damaged cell to essentially 
destroy itself.
As defects in p53-controlled processes cause cells to grow unrestrictedly and can lead to cancer, 
it is a very attractive target for cancer therapies. Cancer drug developments have focused on both 
targeting p53 directly and targeting the proteins that work with p53. Two proteins called Mdm2 and 
SIRT1 are of particular interest. Mdm2 binds to, inactivates, and leads to the degradation of p53. 
SIRT1 can modify p53 and make it more accessible to Mdm2, and is often found in very high levels 
in cancer cells.
In 2012, researchers identified Inauhzin as a small molecule that could potentially be used to 
treat tumors that still have a functional version of the p53 protein. Inauhzin was thought to work by 
inhibiting SIRT1, which increases p53 levels—probably through its effects on Mdm2. This restores 
the cell's ability to control its growth and to die if it is irreparably damaged. However, not all of this 
small molecule's effects on cells can be explained by its interaction with SIRT1.
Now Zhang et al., including some of the researchers involved in the 2012 work, have investigated 
whether Inauhzin also interacts with other proteins in the cell; and Inauhzin was revealed to bind an 
enzyme called IMPDH2. This enzyme is involved in making GTP—a small molecule that is involved in 
many important processes in living cells. Zhang et al. demonstrated that Inauhzin's effect on the 
IMPDH enzyme triggered a response that did not involve the SIRT1 protein, and that ultimately led 
to a decrease in Mdm2 activity and restored p53 activity.
Cancer treatments often include a combination of drugs that target different proteins with the 
goal of reducing the likelihood of a tumor becoming resistant to the treatment. Inauhzin's effect on 
two different proteins that lead to p53 activation not only increases its potency, but also makes it 
less likely that drug resistance will develop.
DOI: 10.7554/eLife.03077.002
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targets in cancer cells. Biotinylated INZ analogs (Figure 1A) were synthesized for these analyses. Here, 
Biotin-INZ was as active as INZ (Zhang et al., 2012b; Zhang et al., 2012a), while Biotin-INZ (O) was 
inactive and thus used as a negative control. Comparison of the most abundant proteins based on 
normalized spectral abundance factor (NSAF) in the cells treated Biotin-INZ vs DMSO or Biotin-INZ (O) 
revealed the high enrichment of IMPDH2 proteins in the former (Figure 1B) with enriched IMPDH2 
peptides shown in Figure 1C. This result was firmly validated by immunoblot (IB) analysis of the pulled 
down proteins, as IMPDH2 was specifically brought down with Biotin-INZ, as well as together with our 
Figure 1. Identification of IMPDH2 as a potential target of INZ. (A) Structure of INZ analogs conjugated with Biotin (Biotin-INZ) used for INZ target 
identification, the oxygen-substituent (Biotin-INZ (O)) as a negative control. (B–C) Cells were treated with indicated compounds individually for 18 hr. 
Cleared cell lysates were incubated with NeutrAvidin beads and washed. The samples from HCT116 cells were then in-beads digested for MS analysis. 
NSAF: normalized spectral abundance factor. Samples were also resolved by SDS-PAGE and subjected to IB with indicated antibodies. (D–F) Knockdown 
of IMPDH2 alleviates INZ induction of p53. HCT116 cells were transfected with scrambled siRNA or IMPDH2 siRNA. 18 hr prior to harvesting, cells were 
treated with 2 µM INZ and harvested for IB with indicated antibodies (D). HCT116 and HCT116−/− cells were exposed to INZ for 72 hr and evaluated by 
WST cell growth assays (E and F). The IC50 values of INZ in the scrambled siRNA and IMPDH2 siRNA transfected cells are 0.87 ± 1.08 µM and 10.24 ± 2.57 µM 
for HCT116 cells, and 5.28 ± 2.43 µM and 12.34 ± 2.02 µM for HCT116−/− cells, respectively (Mean ± SD, n = 3).
DOI: 10.7554/eLife.03077.003
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previously identified SIRT1, but not Biotin-INZ (O) or other controls, in both H460 and HCT116 cells 
(Figure 1C).
To test if IMPDH2 is required for INZ activation of p53, we knocked down IMPDH2 in HCT116 cells 
with specific siRNAs in the presence or absence of INZ. As shown in Figure 1D, knockdown of IMPDH2 
impeded INZ-induced p53 activation as indicated by the reduction of INZ-induced p53, p21, MDM2, and 
Puma levels. Consistently, the growth inhibition by INZ was compromised as the IC50 value for INZ in cell 
growth analysis decreased by almost ∼10-fold when IMPDH2 was knocked down (Figure 1E). Knockdown 
of IMPDH2 in HCT116 cells also conveyed much more significant effect on compromising the cytotox-
icity of INZ compared to p53 null HCT116 (HCT116−/−) cells (Figure 1F), indicating that INZ suppresses 
cancer cell growth mainly by targeting IMPDH2 in the cells and consequently activating the p53 pathway.
Although Biotin-INZ was associated with cellular IMPDH2 (Figure 1), INZ did not appear to affect 
the activity of the purified enzyme (date not shown). This discrepancy could be due to differences 
between the recombinant IMPDH2 in vitro and its native form in cells, as the latter could be regulated 
via post-translational modifications or partner proteins in cells, or INZ might mimic a nucleoside and 
be phosphorylated by a kinase in cells to target IMPDH2. These results also suggest that INZ might not 
directly bind to the active site of this enzyme. These possibilities remain to be addressed in the future.
INZ causes the depletion of nucleostemin and consequent  
ribosomal stress
Our previous study showed that inhibition of IMPDH2 activity by MPA leads to RS and consequent p53 
activation by reducing the level of nucleostemin (NS) (Dai et al., 2008; Lo et al., 2012), a nucleolar 
GTP-binding protein important for rRNA processing (Tsai and McKay, 2005; Lo et al., 2012). The 
association of INZ with IMPDH2 suggested that INZ might have a similar effect. As shown in Figure 2A, 
INZ, but not INZ(O), indeed significantly reduced NS protein levels, which was inversely correlated 
with the INZ induction of p53, p21, MDM2 and cleaved PARP. This result was further confirmed by 
immunofluorescence staining, as INZ, but not INZ(O), led to apparent decrease of nucleolar NS 
(Figure 2B). This decrease was due to the reduction of NS's half-life from >10 hr to <6 hr, as shown in 
Figure 2C, but NS mRNA level did not alter (data not shown). This result, also repeated in HCT116 cell 
lines (data not shown), demonstrates that INZ can destabilize cellular NS.
Next, we tested if the depletion of NS by INZ could induce the interaction of the RPL11 and RPL5 
with MDM2, because we previously showed that the reduction of NS by MPA could induce RS and 
activate p53 by enhancing this interaction (Sun et al., 2008). As shown in Figure 3A, INZ, but not 
INZ(O), indeed enhanced the interaction of MDM2 with RPL5 and RPL11 in H460 cells by immunopre-
cipitation (IP) using anti-MDM2 antibodies followed by IB (Figure 3A). The increased binding of MDM2 
to L11 was true in a reciprocal co-IP using anti-L11 antibodies (Figure 3A). This result indicates that 
INZ-induced p53 activation involves suppression of MDM2 activity by the RPs, further supporting the 
RS-p53 response of INZ-treated cells.
To determine if RPL5 and RPL11 are required for INZ activation of p53, we performed a knockdown 
experiment. As expected, reduction of either RPL5 or RPL11 (data not shown) or both levels by siRNA 
markedly inhibited INZ-induced p53 level, compared to that in scrambled siRNA-transfected cells 
(Figure 3B). Consistently, knocking down RPL5 and RPL11 abrogated INZ-induced p21 and MDM2 
levels (Figure 3B) and apoptosis (Figure 3C), indicating that RPL5 and RPL11 are required for INZ-
induced p53 activation and apoptosis. Also, ribosome profile analysis followed by IB revealed that INZ 
significantly increases the levels of ribosome-free RPL5 and RPL11 (fractions 1–10), whereas it markedly 
reduces the level of polysomes (fractions 37–51) (Figure 3D), suggesting that INZ could suppress ribosome 
biogenesis and possibly protein translation. All together, these results demonstrate that INZ can acti-
vate p53-dependent apoptosis by interfering with ribosome biogenesis through depletion of NS, 
causing RS, which then induces the release of ribosome-free RPL11 and RPL5 that bind to MDM2 and 
consequently inhibit its activity toward p53.
INZ-mediated GTP depletion by targeting IMPDH2
Because Inhibition of IMPDH2 reduces cellular GTP level (Ji et al., 2006), and INZ associates with cellular 
IMPDH2 and reduces nucleolar NS level, consequently causing RS and p53 activation (Figures 1–3), we 
then tested if this INZ effect on p53 could be suppressed by supplementing culture media with extra 
GTP or guanosine. As shown in Figure 4A–B, addition of either GTP or guanosine to cells significantly, 
though partially, alleviated the INZ induction of p53 level and activity as measured by IB analysis of 
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p53, Puma and cleaved PARP. This result is well correlated with Figure 4C, showing that INZ markedly 
reduced the GTP level in H460 cells by 6.3-fold and in HCT116 cells by 3.7-fold, respectively, as meas-
ured by HPLC analysis (Di Pierro et al., 1995). These results indicate that INZ can reduce cellular GTP 
level likely by inhibiting IMPDH2 in cells. Indeed, knockdown of IMPDH2 compromised the GTP deple-
tion by INZ treatment in both p53 wild type and p53 null HCT116 cancer cells (Figure 4D). Since it has 
been shown that NS is very sensitive to cellular GTP level and low GTP level triggers NS re-localization 
from the nucleolus to the nucleoplasm, consequently destabilizing it (Tsai and McKay, 2005; Lo et al., 
2012), these results also suggest that it must be by decreasing cellular GTP level that INZ causes NS 
degradation and consequent RS, leading to p53 activation (Figure 4E).
Cancers are caused by alterations of multiple tumor-associated proteins or genes at the genetic 
and epigenetic levels (Hanahan and Weinberg, 2011), including the p53 pathway (Vousden and 
Prives, 2009). Thus, targeting multiple proteins of one or more signaling pathways in cancers is nec-
essary for developing a more effective cancer therapy. Several individual SIRT1 or IMPDH2 inhibitors 
have been reported (Alcain and Villalba, 2009; Chen et al., 2010). However, dual targeting SIRT1 and 
IMPDH2 by INZ to activate p53 would offer the first paradigm for anti-cancer drug development. Our 
Figure 2. INZ, not its inactive analog INZ (O), treatment, decreases NS expression and destabilizes NS protein. 
H460 cells were treated with 2 μM INZ or its analogue INZ (O) for 20 hr. Cells were harvested and immunoblotted 
with p53, NS, MDM2, p21, cleaved PARP and β-actin (A), or immunostained with anti-NS (green) and anti-p53 (red) 
(B). (C) H460 cells were treated with 2 μM INZ for 9 hr before then 50 μg/ml of CHX was added. Cells were harvested 
at different time points as indicated and assayed for levels of NS.
DOI: 10.7554/eLife.03077.004
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studies (Figures 1–4) together with previously published findings strongly suggest that INZ effectively 
activates p53 and suppresses tumor growth in a p53-dependent fashion by targeting SIRT1 and IMPDH2 
(Figure 4E, (Zhang et al., 2012b)). This dual targeting strategy could also explain why INZ can still 
partially activate p53 in IMPDH2 knockdown or GTP-supplemented cells (Figure 1D and Figure 4A,B), 
although the partial impairment of p53 induction could also be due to the inefficiency of completely 
knockdown IMPDH2 or the possible non-continuous availability of intracellular GTP throughout the 
experiment.
Materials and methods
Cell culture, reagents and antibodies
Human lung carcinoma H460 and human colon cancer HCT116 were cultured in Dulbecco's modi-
fied Eagle's medium supplemented with 10% fetal bovine serum (PBS), penicillin, and streptomycin. 
Figure 3. INZ treatment enhances the interaction of MDM2 with L5 and L11 by inducing ribosome-free form of 
RPL5 and RPL11. (A) H460 cells were treated with 2 μM INZ or INZ (O) for 18 hr. Cell lysates were used for IP with 
anti-MDM2 antibodies or anti-L11 antibodies followed by IB using anti-RPL5, RPL11 or MDM2 antibodies.  
(B and C) HCT116 cells were transfected with siRNAs against RPL5 and RPL11, or control, for 48–72 hr and treated 
with 2 µM INZ 18 hr before harvesting, followed by IB using indicated antibodies or subG1 analysis by flow cytometry. 
(D) Ribosomal profile assay. Cytoplasmic extracts containing ribosomes from H460 cells treated with or without  
2 µM INZ for 18 hr were subjected to a 10–50% linear sucrose gradient sedimentation centrifugation. Fractions 
were collected and subjected to IB with anti-RPL11, anti-RPL5, anti-p53, or anti-MDM2 antibodies. The distribution 
of ribosomes is indicated.
DOI: 10.7554/eLife.03077.005
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Inauhzin (INZ), Inauhzin inactive analogue INZ (O) (INZ9 in [Zhang et al., 2012a]) and Biotinylated 
INZs were synthesized and characterized by NMR and LC-MS as described (Zhang et al., 2012b). The 
purity of the compounds is higher than 90%. Mycophenolic acid (MPA) was purchased from Sigma-
Aldrich (St.Louis, Missouri). Mouse monoclonal anti-p53 (DO-1), rabbit anti-p21 (M19), mouse anti-p21 
(F5), rabbit anti-SIRT1 (H300) and goat anti-RPL11 (N17) were purchased from Santa Cruz Biotechnology, 
Inc. (Dallas, Texas). for immunoblotting. Cleaved PARP, PARP (9542), Puma were from Cell Signaling 
Technologies. Mouse anti-MDM2 (2A10), rabbit anti-RPL11 and anti-RPL5 antibodies were described 
previously (Zeng et al., 1999; Sun et al., 2008). Antibodies for immunostaining were rabbit poly-
clonal anti-p53 (FL-393; Santa Cruz) and monoclonal nucleostemin antibodies (Chemicon, Billerica, 
Massachusetts).
Biotin-avidin pull down assays
Cells were plated on 10 cm dishes and treated with compounds at about 60–70% confluence. Cells were 
harvested and lysed in the PBS buffer with 0.1% (wt/vol) NP40 (freshly adding protease inhibitors and 1 mM 
DTT). Incubate the cell lysate with 25 μL of NeutrAvidin Agarose beads (Thermo Scientific, Waltham, 
Massachusetts) (beads volume) in for 2 hr at 4°C with end-over-end mixing. Centrifuge at 13,000 rpm 
for 10 s at 4°C in a microcentrifuge. The beads were washed three times with 0.5% (wt/vol) NP-40, 
Figure 4. GTP or guanosine lessens INZ activation of p53 in cells. (A and B) H460 cells were pretreated with GTP or 
guanosine for 2 hr before the addition of 2 μM INZ. Cells were harvested and followed by IB with indicated 
antibodies. (C) Effect of INZ on cellular GTP level. The nucleotides were extracted from H460 or HCT116 cells 
treated with 2 μM INZ by 80% acetonitrile and SPE column. Samples were subjected to GTP analysis by HPLC. 
Results of quantification of HPLC spectra presented in arbitrary units (AU) were presented in this Table. (D) HCT116−/− 
and HCT116 cells transfected IMPDH2 siRNA (SiIMPDH2) or scrambled siRNA (SiControl) were exposed to INZ 
for 18 hr, and cellular GTP was extracted, measured and quantitated by LC-MS/MS. Values represent means  
±SD (n = 2). (E) A schematic diagram of the role of IMPDH2 in INZ-induced ribosomal stress (RS) and p53 activa-
tion. IMPDH2 is a rate-limiting enzyme in the de novo guanine nucleotide biosynthesis. INZ reduced the levels of 
cellular GTP and NS by targeting IMPDH2 (or its complex), resulting in RS that leads to the enhancement of the 
RPL11/RPL5-MDM2 interaction, consequently MDM2 inactivation and p53 activation.
DOI: 10.7554/eLife.03077.006
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0.2% (wt/vol) Tween20/Tris buffered saline and then subjected to on-beads digestion and mass spec-
trometry as shown below.
On-bead Trypsin digestion
On-bead digestions were performed to release the proteins and resulting tryptic peptides from the 
NeutrAvidin beads. In brief, beads were resuspended in 100 μl of 50 mM ammonium bicarbonate pH 8.0 
followed by the addition of 1 μg of Trypsin Gold (Promega, Madison, Wisconsin). The samples were then 
incubated at 37°C for 12 hr with shaking. Following digestion, samples were run through spin columns 
to remove any trace of the residual purification resin. The digestions were then quenched through the 
addition of 8 μL of formic acid.
MudPIT analyses
Protein samples from cells that were MOCK treated with Biotin-INZ (O) or treated with DMSO or 
Biotin-INZ were pressure loaded onto three-phase MudPIT columns containing Aqua C18 and Luna 
SCX resins (Phenomenex, Torrance, California) as previously described (Mosley et al., 2009, 2011). 
Ten-step MudPIT was performed using increasing concentrations of ammonium acetate to initiate 
each step followed by a 100-min gradient of 0–80% acetonitrile. All samples were analyzed on a 
LTQ Velos mass spectrometer (Thermo Scientific) with the dynamic exclusion set to 90 s. The spectra 
obtained through MudPIT analysis were searched through Proteome Discoverer 1.3 (Thermo Scientific) 
using SEQUEST as the peptide-spectrum matching algorithm against the Human NCBI 11-22-10 data-
base containing 29,535 protein sequences. In addition to the human proteins, the database also con-
tained ∼140 common contaminant sequences for proteins such as keratins, BSA, and proteolytic 
enzymes. Using Proteome Discoverer 1.3, all peptides were required to pass a 2% false discovery 
threshold. The number of spectra obtained for proteins found to interact with Biotin-INZ was com-
pared to the levels of spectra for those same proteins observed in MOCK and DMSO treatments to 
ensure that the candidate interacting proteins are detected at levels higher than background.
Immunoblotting
Cells were seeded in 6-well plates. All compounds were dissolved in DMSO and diluted directly into 
the medium to the indicated concentrations, and 0.1% DMSO was used as a control. After incubation 
with the compounds for the indicated times, cells were harvested and lysed in 50 mM Tris-HCl pH 8.0, 
150 mM NaCl, 5 mM EDTA, 0.5% NP-40 supplemented with 2 mM DTT and 1 mM PMSF. An equal 
amount of protein samples (50 μg) was subjected to SDS-PAGE and transferred to a PVDF membrane 
(PALL Life Science, Port Washington, New York). The membranes with transferred proteins were 
probed with primary antibodies followed by horseradish-peroxidase-conjugated secondary antibody 
(1:10,000; Pierce). The blots were then developed using an enhanced chemiluminescence detection 
kit (Thermo Scientific), and signals were visualized by Omega 12iC Molecular Image System (UltraLUM, 
Claremont, California).
Immunofluorescence staining
H460 cells at 50–70% confluence were treated with 2 µM of Inauhzin (INZ) or Inauhzin (O) (INZ (O)) for 
16 hr. Cells were fixed in 4% formaldehyde/PBS for 10 min, permeabilized and blocked with 0.3% 
Triton-100, 8%BSA/PBS. The primary antibodies used were monoclonal nucleostemin antibodies in 
1:250 dilution and polyclonal p53 antibodies in 1: 500 dilution according to the manufactural instruc-
tion. Images were taken with a Zeiss Axiovert 200M fluorescent microscope (Germany).
RNA interference
Control scrambled siRNA (Santa Cruz), or siRNA specific to IMPDH2 (Santa Cruz and Ambion, Grand 
Island, New York) were commercially purchased. These siRNAs (60 nM) were introduced into cells 
using METAFECTENE SI following the manufacturer's protocol (Biontex, Germany). Cells were treated 
with INZ for IB, cell viability assays and FACS analysis.
Cell viability assay
To assess cell growth, the cell counting kit (Dojindo Molecular Technologies Inc., Rockville, Maryland) 
was used according to manufacturer's instructions. Cell suspensions were seeded at 5000 cells per 
well in 96-well culture plates and incubated overnight at 37°C. Compounds were added into the plates 
and incubated at 37°C for 72 hr. Cell growth inhibition was determined by adding WST-8 at a final 
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concentration of 10% to each well, and the absorbance of the samples was measured at 450 nm using 
a Microplate Reader (Molecular Device, SpectraMax M5e (Sunnyvale, California)).
FACS analysis
Cells were harvested, fixed in 70% ethanol overnight and analyzed by propidium iodide (PI) staining and 
flow cytometry (FACS Calibur, Becton Dickinson, Washington, DC) as previously described (Riccardi 
and Nicoletti, 2006).
Ribosomal profiling analysis
Cytosolic extractions, sucrose gradient sedimentation of polysomes, and analysis of the polysomes/
mRNPs distribution of proteins were carried out as previously described (Sun et al., 2007; Dai et al., 
2012; Ingolia et al., 2012). Briefly, cells were incubated with 100 μg/ml of cycloheximide for 15 min. 
Cells were homogenized in polysome lysis buffer containing 30 mM Tris–HCl (pH 7.4), 10 mM MgCl2, 
100 mM KCl, 0.3% NP-40, 100 μg/ml of cycloheximide, 30 units/ml RNasin inhibitor, 1 mM DTT, 1 mM 
phenylmethylsulfonyl fluoride, 0.25 μg/ml pepstatin A. After incubation on ice for 5 min, cell lysates 
were centrifuged at 1300×g at 4°C for 10 min. Supernatants were subjected to sedimentation cen-
trifugation in a 10–50% sucrose gradient solution containing 30 mM Tris–HCl (pH 7.4), 10 mM MgCl2, 
100 mM KCl in a Beckman SW41 rotor at 37,000 rpm at 4°C for 2 hr. Fractions were collected and 
absorbance of RNA at 254 nm was recorded using BR-188 Density Gradient Fractionation System 
(Brandel, Gaithersburg, Maryland) to analyze the distribution of polysomes and monosomes as 
described (Esposito et al., 2010).
Extraction and determination of cellular GTP
We adapted previously established whole cell assays using HPLC to determine cellular GTP level (Di 
Pierro et al., 1995; Nakajima et al., 2010). After 48 hr of growth, cells were treated with 2 μM INZ for 
18 hr. Cellular nucleotides were extracted from cell monolayers by addition of ice-cold 80% acetoni-
trile for 1 hr. The extracts were centrifuged to pellet the cellular debris and the cleared supernatant 
was loaded to the SPE column (SAX column, Sigma–Aldrich). The elutes were analyzed by Agilent 
1100 series liquid chromatograph system with a C18 reversed-phase column (Agilent Zorbax 
Extend-C18, 5 µM, 4.6 × 150 mm). A gradient elution from 0%B to 50%B in 70 min was used at a flow 
rate of 1 ml/min (solvent A: 0.05M KH2PO4, 0.005M tetrabutylammonium, pH5.5; B: 50% acetonitrile 
in 0.05M KH2PO4, 0.005M tetrabutylammonium, pH 7.0). The GTP level was also analyzed by a nano-
ACQUITY UPLC/Synapt HDMS mass spectrometer (Waters, Milford, Massachusetts) using acetonitrile/
water (0.05M NH4Ac buffer solution at pH = 5.5) as the mobile phase with a flow rate of 0.5 μl/min.
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